Intellia Therapeutics Inc (NTLA) USD0.0001

Sell:$10.31Buy:$10.32$0.20 (1.98%)

NASDAQ:0.28%
Prices delayed by at least 15 minutes
Sell:$10.31
Buy:$10.32
Change:$0.20 (1.98%)
Deal now
Prices delayed by at least 15 minutes
Sell:$10.31
Buy:$10.32
Change:$0.20 (1.98%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Key people

John M. Leonard
President, Chief Executive Officer, Director
Edward J. Dulac
Chief Financial Officer, Executive Vice President, Treasurer and Principal Financial Officer
Eliana Clark
Executive Vice President, Chief Technology Officer
Birgit Schultes
Executive Vice President, Chief Scientific Officer
Laura Sepp-Lorenzino
Executive Vice President, Chief Scientific Officer
James Basta
Executive Vice President, General Counsel, Corporate Secretary
Derek Hicks
Executive Vice President, Chief Business Officer
David Lebwohl
Executive Vice President, Chief Medical Officer
Michael P. Dube
Chief Accounting Officer, Vice President
Frank A. G. M. Verwiel
Independent Chairman of the Board
Muna Bhanji
Independent Director
William J. Chase
Independent Director
Frederick E. Cohen
Independent Director
Brian M. Goff
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45826J1051
  • Market cap
    $1.02bn
  • Employees
    526
  • Shares in issue
    101.85m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.